

# France

## Tuberculosis profile

Population 2016

65 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.41 (0.39–0.43)	0.63 (0.6–0.67)
Mortality (HIV+TB only)	0.11 (0.056–0.18)	0.17 (0.09–0.27)
Incidence (includes HIV+TB)	5 (4.4–5.6)	7.7 (6.7–8.6)
Incidence (HIV+TB only)	0.67 (0.4–1)	1 (0.63–1.6)
Incidence (MDR/RR-TB)**	0.082 (0.059–0.1)	0.13 (0.09–0.16)

Estimated TB incidence by age and sex (thousands)\*, 2016

	0-14 years	> 14 years	Total
Females	0.22 (0.19–0.24)	1.8 (1.5–2)	2 (1.7–2.2)
Males	0.24 (0.21–0.27)	2.7 (2.4–3.1)	3 (2.6–3.4)
Total	0.46 (0.4–0.52)	4.5 (3.9–5.1)	5 (4.4–5.6)

TB case notifications, 2016

Total cases notified	4 958
Total new and relapse	4 675
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	
- % pulmonary	71%
- % bacteriologically confirmed among pulmonary	70%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	94% (84–110)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.1 (0.09–0.12)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive		
- on antiretroviral therapy		

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			63 (46–79)
Estimated % of TB cases with MDR/RR-TB	1% (0.65–1.5)	10% (7.1–15)	
% notified tested for rifampicin resistance	70%	113%	4 197
MDR/RR-TB cases tested for resistance to second-line drugs			69
Laboratory-confirmed cases		MDR/RR-TB: 71, XDR-TB: 6	
Patients started on treatment ****		MDR/RR-TB: 71, XDR-TB: 6	

Treatment success rate and cohort size

	Success	Cohort
New cases registered in 2015		
Previously treated cases registered in 2015		
HIV-positive TB cases registered in 2015		
MDR/RR-TB cases started on second-line treatment in 2014		
XDR-TB cases started on second-line treatment in 2014		

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2017

National TB budget (US\$ millions)
------------------------------------


\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history


\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New cases  
— Previously treated cases  
— HIV-positive — MDR/RR-TB — XDR-TB